A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

ConditionCOPD

Trial statusNot yet recruiting

Trial phasePhase 2

Trial typeInterventional

Biological sexAll

Age40-80

SponsorGuangdong Hengrui Pharmaceutical Co., Ltd

About this trial

The study is being conducted to evaluate the efficacy and safety of HRS-9821 for patients with COPD, and to explore the reasonable dosage of HRS-9821 for patients with COPD.

Eligibility criteria

Qualifiers

Age ≥ 40 years old and < 80 years old, male or female.

Meet the weight standard.

Smoking history ≥ 10 pack-years.

COPD has been diagnosed ≥ 1 year.

Disqualifiers

History of life-threatening COPD.

Other pulmonary diseases that may affect the efficacy evaluation of this study.

Concurrent diseases other than COPD that may affect lung function.

History of asthma.

Trial design

Treatments tested in this trial

HRS-9821 Inhalation Suspension
HRS-9821 Placebo Inhalation Suspension

Treatment groups

90 Participants

are divided into 4 treatment groups

Sponsors and collaborators

Guangdong Hengrui Pharmaceutical Co., Ltd

Lead sponsor

Source ClinicalTrials.gov